{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.7","upperLimit":"38.6","value":"20.0"},{"groupId":"OG001","lowerLimit":"3.8","upperLimit":"30.7","value":"13.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Percentage of participants achieving CR as defined by the 2017 European Leukemia Net (ELN) Response Criteria for all participants with AML and modified International Working Group (IWG) criteria (2006) for all participants with MDS in the expansion cohorts.\n\nFor AML cohort, CR was defined as neutrophils ≥ 1 x 10\\^9/L, platelets ≥ 1 x 10\\^11/L, percentage of bone marrow blasts (BMB) \\<5% with no peripheral blasts and no blasts with Auer rods, no extramedullary disease (EMD), and transfusion independent.\n\nFor MDS cohort, CR was defined as having responses of hemoglobin ≥11 g/dL, neutrophils ≥1 x 10\\^9/L, platelets ≥1 x 10\\^11/L, percentage of blasts = 0%, percentage of BMB≤5%, and normal maturation of all cell lines (note if has persistent dysplasia), and all responses must last at least 4 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG000","title":"AML Cohort"},{"description":"Participants received SC or IV administration of azacitidine with a starting dose of 75 mg/m2/day for 7 days every 28 days, and received daily oral administration of glasdegib at home with a starting dose of 100 mg QD.","id":"OG001","title":"MDS Cohort"}],"paramType":"NUMBER","populationDescription":"The full analysis population included all participants who received at least 1 dose of any study treatment.","reportingStatus":"POSTED","timeFrame":"maximum of 23 months in AML cohort and 34 months in MDS cohort","title":"Percentage of Participants Achieving Complete Remission (CR) in the AML and MDS Cohorts","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}